Azenta
AZTA · Life Sciences Tools & Services
$36.50
1.4%Medpace
MEDP · Life Sciences Tools & Services
$669.20
2.3%The short version
- Medpace is the larger business, with $2.5B of revenue in fiscal 2025 against $594M for Azenta, about 4.3 times as much.
- Medpace grew revenue faster (20.0%, against 3.6%).
- Medpace kept more of each dollar of sales as operating profit (21.1% operating margin, against −4.5% operating margin).
- Medpace turned more of its sales into free cash flow (27.0% FCF margin, against 6.5% FCF margin).
| Latest fiscal year | AZTA · FY25 | MEDP · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.7B | $19.0B |
| Revenue | $594M | $2.5B |
| Free cash flow | $38.3M | $682M |
| Net income | −$55.8M | $451M |
| Growth | ||
| Revenue growth | 3.6% | 20.0% |
| 5-year growth | 8.9% | 22.3% |
| Share count change | −13.7% | −7.8% |
| Profitability | ||
| Gross margin | 45.5% | — |
| Operating margin | −4.5% | 21.1% |
| Net margin | −9.4% | 17.8% |
| FCF margin | 6.5% | 27.0% |
| Return on capital | — | — |
| Return on equity | −3.2% | 70.2% |
| Balance sheet | ||
| Net debt | — | −$497M |
| Net debt / EBITDA | — | −0.9x |
| Dividends and buybacks | $0.0M | $917M |
| Valuation & quality | ||
| P/E | — | 37.2x |
| Piotroski F-score | — | 4 |
FY16
AZTA $434M
MEDP $422M
FY17
AZTA $528M
MEDP $436M
FY18
AZTA $632M
MEDP $705M
FY19
AZTA $334M
MEDP $861M
FY20
AZTA $389M
MEDP $926M
FY21
AZTA $514M
MEDP $1.1B
FY22
AZTA $556M
MEDP $1.5B
FY23
AZTA $552M
MEDP $1.9B
FY24
AZTA $573M
MEDP $2.1B
FY25
AZTA $594M
MEDP $2.5B
AZTA
MEDP
FY16
AZTA −3.9%
MEDP 12.5%
FY17
AZTA 2.7%
MEDP 14.9%
FY18
AZTA 5.0%
MEDP 14.3%
FY19
AZTA −14.2%
MEDP 14.8%
FY20
AZTA −9.4%
MEDP 18.0%
FY21
AZTA −6.1%
MEDP 17.4%
FY22
AZTA −4.5%
MEDP 19.1%
FY23
AZTA −11.1%
MEDP 17.9%
FY24
AZTA −8.9%
MEDP 21.2%
FY25
AZTA −4.5%
MEDP 21.1%
AZTA
MEDP
FY16
AZTA $26.7M
MEDP $78.2M
FY17
AZTA $83.6M
MEDP $85.7M
FY18
AZTA $61.2M
MEDP $141M
FY19
AZTA $67.0M
MEDP $184M
FY20
AZTA −$2.1M
MEDP $227M
FY21
AZTA $97.1M
MEDP $235M
FY22
AZTA −$539M
MEDP $351M
FY23
AZTA −$33.6M
MEDP $397M
FY24
AZTA $12.4M
MEDP $572M
FY25
AZTA $38.3M
MEDP $682M
AZTA
MEDP
FY16
AZTA —
MEDP 4.2%
FY17
AZTA —
MEDP 6.2%
FY18
AZTA —
MEDP 11.6%
FY19
AZTA −4.8%
MEDP 16.4%
FY20
AZTA −3.0%
MEDP 25.7%
FY21
AZTA −2.3%
MEDP 35.1%
FY22
AZTA —
MEDP 53.7%
FY23
AZTA —
MEDP 78.7%
FY24
AZTA —
MEDP 161.7%
FY25
AZTA —
MEDP —
AZTA
MEDP
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.